Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 226

1.

Fsp3-rich and diverse fragments inspired by natural products as a collection to enhance fragment-based drug discovery.

Hanby AR, Troelsen NS, Osberger TJ, Kidd SL, Mortensen KT, Spring DR.

Chem Commun (Camb). 2020 Jan 27. doi: 10.1039/c9cc09796a. [Epub ahead of print]

PMID:
31984987
2.

Genomic and expression analyses define MUC17 and PCNX1 as predictors of chemotherapy response in breast cancer.

Al Amri WS, Allinson LM, Baxter DE, Bell SM, Hanby AM, Jones SJ, Shaaban AM, Stead LF, Verghese ET, Hughes TA.

Mol Cancer Ther. 2019 Dec 26. pii: molcanther.0940.2019. doi: 10.1158/1535-7163.MCT-19-0940. [Epub ahead of print]

PMID:
31879365
3.

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL): an overview of presentation and pathogenesis and guidelines for pathological diagnosis and management.

Jones JL, Hanby AM, Wells C, Calaminici M, Johnson L, Turton P, Deb R, Provenzano E, Shaaban A, Ellis IO, Pinder SE; National Co-ordinating Committee of Breast Pathology.

Histopathology. 2019 Dec;75(6):787-796. doi: 10.1111/his.13932. Epub 2019 Oct 6. Review.

PMID:
31166611
4.

Endogenous Production of IL1B by Breast Cancer Cells Drives Metastasis and Colonization of the Bone Microenvironment.

Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, Nutter F, Wilkinson JM, Spicer-Hadlington AR, Liu X, Bradbury SMJ, Hambley L, Cookson V, Allocca G, Kruithof de Julio M, Coleman RE, Brown JE, Holen I, Ottewell PD.

Clin Cancer Res. 2019 May 1;25(9):2769-2782. doi: 10.1158/1078-0432.CCR-18-2202. Epub 2019 Jan 22.

PMID:
30670488
5.

Identification and validation of DOCK4 as a potential biomarker for risk of bone metastasis development in patients with early breast cancer.

Westbrook JA, Wood SL, Cairns DA, McMahon K, Gahlaut R, Thygesen H, Shires M, Roberts S, Marshall H, Oliva MR, Dunning MJ, Hanby AM, Selby PJ, Speirs V, Mavria G, Coleman RE, Brown JE.

J Pathol. 2019 Mar;247(3):381-391. doi: 10.1002/path.5197. Epub 2019 Jan 25.

6.

Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme.

Lindsay CR, Shaw EC, Blackhall F, Blyth KG, Brenton JD, Chaturvedi A, Clarke N, Dick C, Evans TRJ, Hall G, Hanby AM, Harrison DJ, Johnston SRD, Mason MD, Morton D, Newton-Bishop J, Nicholson AG, Oien KA, Popat S, Rassl D, Sharpe R, Taniere P, Walker I, Wallace WA, West NP, Butler R, Gonzalez de Castro D, Griffiths M, Johnson PWM.

ESMO Open. 2018 Sep 5;3(6):e000408. doi: 10.1136/esmoopen-2018-000408. eCollection 2018.

7.

Management and 5-year outcomes in 9938 women with screen-detected ductal carcinoma in situ: the UK Sloane Project.

Thompson AM, Clements K, Cheung S, Pinder SE, Lawrence G, Sawyer E, Kearins O, Ball GR, Tomlinson I, Hanby A, Thomas JSJ, Maxwell AJ, Wallis MG, Dodwell DJ; Sloane Project Steering Group (NHS Prospective Study of Screen-Detected Non-invasive Neoplasias).

Eur J Cancer. 2018 Sep;101:210-219. doi: 10.1016/j.ejca.2018.06.027. Epub 2018 Aug 6.

PMID:
30092498
8.

Neoadjuvant Endocrine Therapy in Breast Cancer Upregulates the Cytotoxic Drug Pump ABCG2/BCRP, and May Lead to Resistance to Subsequent Chemotherapy.

Baxter DE, Kim B, Hanby AM, Verghese ET, Sims AH, Hughes TA.

Clin Breast Cancer. 2018 Dec;18(6):481-488. doi: 10.1016/j.clbc.2018.07.002. Epub 2018 Jul 6.

9.

Harnessing citizen science through mobile phone technology to screen for immunohistochemical biomarkers in bladder cancer.

Smittenaar P, Walker AK, McGill S, Kartsonaki C, Robinson-Vyas RJ, McQuillan JP, Christie S, Harris L, Lawson J, Henderson E, Howat W, Hanby A, Thomas GJ, Bhattarai S, Browning L, Kiltie AE.

Br J Cancer. 2018 Jul;119(2):220-229. doi: 10.1038/s41416-018-0156-0. Epub 2018 Jul 11.

10.

Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer.

Coulson-Gilmer C, Humphries MP, Sundara Rajan S, Droop A, Jackson S, Condon A, Cserni G, Jordan LB, Jones LJ, Kanthan R, Di Benedetto A, Mottolese M, Provenzano E, Kulka J, Shaaban AM, Hanby AM, Speirs V.

J Pathol Clin Res. 2018 Oct;4(4):241-249. doi: 10.1002/cjp2.106. Epub 2018 Aug 23. Erratum in: J Pathol Clin Res. 2019 Jul;5(3):213.

11.

Interobserver variation in the diagnosis of fibroepithelial lesions of the breast: a multicentre audit by digital pathology.

Dessauvagie BF, Lee AHS, Meehan K, Nijhawan A, Tan PH, Thomas J, Tie B, Treanor D, Umar S, Hanby AM, Millican-Slater R.

J Clin Pathol. 2018 Aug;71(8):672-679. doi: 10.1136/jclinpath-2017-204977. Epub 2018 Feb 13.

12.

Associations Between Serum Bone Biomarkers in Early Breast Cancer and Development of Bone Metastasis: Results From the AZURE (BIG01/04) Trial.

Brown J, Rathbone E, Hinsley S, Gregory W, Gossiel F, Marshall H, Burkinshaw R, Shulver H, Thandar H, Bertelli G, Maccon K, Bowman A, Hanby A, Bell R, Cameron D, Coleman R.

J Natl Cancer Inst. 2018 Aug 1;110(8):871-879. doi: 10.1093/jnci/djx280.

13.

Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.

Copson ER, Maishman TC, Tapper WJ, Cutress RI, Greville-Heygate S, Altman DG, Eccles B, Gerty S, Durcan LT, Jones L, Evans DG, Thompson AM, Pharoah P, Easton DF, Dunning AM, Hanby A, Lakhani S, Eeles R, Gilbert FJ, Hamed H, Hodgson S, Simmonds P, Stanton L, Eccles DM.

Lancet Oncol. 2018 Feb;19(2):169-180. doi: 10.1016/S1470-2045(17)30891-4. Epub 2018 Jan 11.

14.

MED12, TERT promoter and RBM15 mutations in primary and recurrent phyllodes tumours.

Garcia-Dios DA, Levi D, Shah V, Gillett C, Simpson MA, Hanby A, Tomlinson I, Sawyer EJ.

Br J Cancer. 2018 Jan;118(2):277-284. doi: 10.1038/bjc.2017.450. Epub 2018 Jan 9.

15.

Confusion Over Differences in Registration and Randomization Criteria for the LORIS (Low-Risk DCIS) Trial.

Rea D, Francis A, Wallis M, Thomas J, Bartlett J, Bowden S, Dodwell D, Fallowfield L, Gaunt C, Hanby A, Jenkins V, Matthews L, Pinder S, Pirrie S, Reed M, Wilcox M, Roberts T, Kirwan C, Brookes C, Fairbrother P, Billingham L, Evans A, Young J.

Ann Surg Oncol. 2017 Dec;24(Suppl 3):566-567. doi: 10.1245/s10434-017-6174-y. Epub 2017 Nov 28. No abstract available.

PMID:
29185098
16.

Effect of MAF amplification on treatment outcomes with adjuvant zoledronic acid in early breast cancer: a secondary analysis of the international, open-label, randomised, controlled, phase 3 AZURE (BIG 01/04) trial.

Coleman R, Hall A, Albanell J, Hanby A, Bell R, Cameron D, Dodwell D, Marshall H, Jean-Mairet J, Tercero JC, Rojo F, Gregory W, Gomis RR.

Lancet Oncol. 2017 Nov;18(11):1543-1552. doi: 10.1016/S1470-2045(17)30603-4. Epub 2017 Oct 13.

17.

CIP2A expression predicts recurrences of tamoxifen-treated breast cancer.

Baldacchino S, Wastall LM, Saliba C, Hughes TA, Scerri C, Berwick A, Speirs V, Hanby AM, Grech G.

Tumour Biol. 2017 Oct;39(10):1010428317722064. doi: 10.1177/1010428317722064.

18.

Digital pathology for the primary diagnosis of breast histopathological specimens: an innovative validation and concordance study on digital pathology validation and training.

Williams BJ, Hanby A, Millican-Slater R, Nijhawan A, Verghese E, Treanor D.

Histopathology. 2018 Mar;72(4):662-671. doi: 10.1111/his.13403. Epub 2017 Dec 11.

19.

Characterisation of male breast cancer: a descriptive biomarker study from a large patient series.

Humphries MP, Sundara Rajan S, Honarpisheh H, Cserni G, Dent J, Fulford L, Jordan LB, Jones JL, Kanthan R, Litwiniuk M, Di Benedetto A, Mottolese M, Provenzano E, Shousha S, Stephens M, Kulka J, Ellis IO, Titloye AN, Hanby AM, Shaaban AM, Speirs V.

Sci Rep. 2017 Mar 28;7:45293. doi: 10.1038/srep45293.

20.

The BIG 2.04 MRC/EORTC SUPREMO Trial: pathology quality assurance of a large phase 3 randomised international clinical trial of postmastectomy radiotherapy in intermediate-risk breast cancer.

Thomas JS, Hanby AM, Russell N, van Tienhoven G, Riddle K, Anderson N, Cameron DA, Bartlett JM, Piper T, Cunningham C, Canney P, Kunkler IH; SUPREMO Trial Management Group.

Breast Cancer Res Treat. 2017 May;163(1):63-69. doi: 10.1007/s10549-017-4145-4. Epub 2017 Feb 11.

21.

Crowdsourcing for translational research: analysis of biomarker expression using cancer microarrays.

Lawson J, Robinson-Vyas RJ, McQuillan JP, Paterson A, Christie S, Kidza-Griffiths M, McDuffus LA, Moutasim KA, Shaw EC, Kiltie AE, Howat WJ, Hanby AM, Thomas GJ, Smittenaar P.

Br J Cancer. 2017 Jan 17;116(2):237-245. doi: 10.1038/bjc.2016.404. Epub 2016 Dec 13.

22.

Expression of phosphorylated eIF4E-binding protein 1, but not of eIF4E itself, predicts survival in male breast cancer.

Millican-Slater RA, Sayers CD, Hanby AM, Hughes TA.

Br J Cancer. 2016 Jul 26;115(3):339-45. doi: 10.1038/bjc.2016.178. Epub 2016 Jun 9.

23.

Management of breast cancer in an Asian man with post-traumatic stress disorder: a case report.

Patel F, Achuthan R, Hyklova L, Hanby AM, Speirs V.

J Med Case Rep. 2016 Mar 29;10(1):77. doi: 10.1186/s13256-016-0864-0.

24.

Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness.

Avgustinova A, Iravani M, Robertson D, Fearns A, Gao Q, Klingbeil P, Hanby AM, Speirs V, Sahai E, Calvo F, Isacke CM.

Nat Commun. 2016 Jan 18;7:10305. doi: 10.1038/ncomms10305.

25.

CAPG and GIPC1: Breast Cancer Biomarkers for Bone Metastasis Development and Treatment.

Westbrook JA, Cairns DA, Peng J, Speirs V, Hanby AM, Holen I, Wood SL, Ottewell PD, Marshall H, Banks RE, Selby PJ, Coleman RE, Brown JE.

J Natl Cancer Inst. 2016 Jan 12;108(4). doi: 10.1093/jnci/djv360. Print 2016 Apr. Erratum in: J Natl Cancer Inst. 2016 Mar;108(3). pii: djw017. doi: 10.1093/jnci/djw017.

26.

3-D tissue modelling and virtual pathology as new approaches to study ductal carcinoma in situ.

Booth ME, Nash CE, Roberts NP, Magee DR, Treanor D, Hanby AM, Speirs V.

Altern Lab Anim. 2015 Dec;43(6):377-83.

PMID:
26753940
27.

Down-Regulation of miR-92 in Breast Epithelial Cells and in Normal but Not Tumour Fibroblasts Contributes to Breast Carcinogenesis.

Smith L, Baxter EW, Chambers PA, Green CA, Hanby AM, Hughes TA, Nash CE, Millican-Slater RA, Stead LF, Verghese ET, Speirs V.

PLoS One. 2015 Oct 5;10(10):e0139698. doi: 10.1371/journal.pone.0139698. eCollection 2015.

28.

Lack of CD151/integrin α3β1 complex is predictive of poor outcome in node-negative lobular breast carcinoma: opposing roles of CD151 in invasive lobular and ductal breast cancers.

Romanska HM, Potemski P, Krakowska M, Mieszkowska M, Chaudhri S, Kordek R, Kubiak R, Speirs V, Hanby AM, Sadej R, Berditchevski F.

Br J Cancer. 2015 Nov 3;113(9):1350-7. doi: 10.1038/bjc.2015.344. Epub 2015 Sep 29.

29.

Chemotherapy induces Notch1-dependent MRP1 up-regulation, inhibition of which sensitizes breast cancer cells to chemotherapy.

Kim B, Stephen SL, Hanby AM, Horgan K, Perry SL, Richardson J, Roundhill EA, Valleley EM, Verghese ET, Williams BJ, Thorne JL, Hughes TA.

BMC Cancer. 2015 Sep 11;15:634. doi: 10.1186/s12885-015-1625-y.

30.

Addressing overtreatment of screen detected DCIS; the LORIS trial.

Francis A, Thomas J, Fallowfield L, Wallis M, Bartlett JM, Brookes C, Roberts T, Pirrie S, Gaunt C, Young J, Billingham L, Dodwell D, Hanby A, Pinder SE, Evans A, Reed M, Jenkins V, Matthews L, Wilcox M, Fairbrother P, Bowden S, Rea D.

Eur J Cancer. 2015 Nov;51(16):2296-303. doi: 10.1016/j.ejca.2015.07.017. Epub 2015 Aug 18.

PMID:
26296293
31.

Crowdsourcing the General Public for Large Scale Molecular Pathology Studies in Cancer.

Candido Dos Reis FJ, Lynn S, Ali HR, Eccles D, Hanby A, Provenzano E, Caldas C, Howat WJ, McDuffus LA, Liu B, Daley F, Coulson P, Vyas RJ, Harris LM, Owens JM, Carton AF, McQuillan JP, Paterson AM, Hirji Z, Christie SK, Holmes AR, Schmidt MK, Garcia-Closas M, Easton DF, Bolla MK, Wang Q, Benitez J, Milne RL, Mannermaa A, Couch F, Devilee P, Tollenaar RA, Seynaeve C, Cox A, Cross SS, Blows FM, Sanders J, de Groot R, Figueroa J, Sherman M, Hooning M, Brenner H, Holleczek B, Stegmaier C, Lintott C, Pharoah PD.

EBioMedicine. 2015 May 9;2(7):681-9. doi: 10.1016/j.ebiom.2015.05.009. eCollection 2015 Jul.

32.

A Rac/Cdc42 exchange factor complex promotes formation of lateral filopodia and blood vessel lumen morphogenesis.

Abraham S, Scarcia M, Bagshaw RD, McMahon K, Grant G, Harvey T, Yeo M, Esteves FOG, Thygesen HH, Jones PF, Speirs V, Hanby AM, Selby PJ, Lorger M, Dear TN, Pawson T, Marshall CJ, Mavria G.

Nat Commun. 2015 Jul 1;6:7286. doi: 10.1038/ncomms8286.

33.

Development and characterisation of a 3D multi-cellular in vitro model of normal human breast: a tool for cancer initiation studies.

Nash CE, Mavria G, Baxter EW, Holliday DL, Tomlinson DC, Treanor D, Novitskaya V, Berditchevski F, Hanby AM, Speirs V.

Oncotarget. 2015 May 30;6(15):13731-41.

34.

Inflammatory breast cancer: time to standardise diagnosis assessment and management, and for the joining of forces to facilitate effective research.

Rea D, Francis A, Hanby AM, Speirs V, Rakha E, Shaaban A, Chan S, Vinnicombe S, Ellis IO, Martin SG, Jones LJ, Berditchevski F; UK Inflammatory Breast Cancer Working group.

Br J Cancer. 2015 Apr 28;112(9):1613-5. doi: 10.1038/bjc.2015.115. Epub 2015 Mar 31. No abstract available.

35.

Updated UK Recommendations for HER2 assessment in breast cancer.

Rakha EA, Pinder SE, Bartlett JM, Ibrahim M, Starczynski J, Carder PJ, Provenzano E, Hanby A, Hales S, Lee AH, Ellis IO; National Coordinating Committee for Breast Pathology.

J Clin Pathol. 2015 Feb;68(2):93-9. doi: 10.1136/jclinpath-2014-202571. Epub 2014 Dec 8.

36.

Variations in the management of the axilla in screen-detected ductal carcinoma in situ: evidence from the UK NHS breast screening programme audit of screen detected DCIS.

Nicholson S, Hanby A, Clements K, Kearins O, Lawrence G, Dodwell D, Bishop H, Thompson A; Sloane Project Steering Group.

Eur J Surg Oncol. 2015 Jan;41(1):86-93. doi: 10.1016/j.ejso.2014.09.003. Epub 2014 Oct 16.

PMID:
25441934
37.

Reponse to: comment on, 'Tumour-stroma ratio (TSR) in oestrogen-positive breast cancer patients'.

Downey CL, Simpkins SA, Holliday DL, Jones JL, Jordan LB, Kulka J, Hanby AM, Speirs V.

Br J Cancer. 2015 May 26;112(11):1833-4. doi: 10.1038/bjc.2014.571. Epub 2014 Nov 13. No abstract available.

38.

Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer.

Roylance R, Endesfelder D, Jamal-Hanjani M, Burrell RA, Gorman P, Sander J, Murphy N, Birkbak NJ, Hanby AM, Speirs V, Johnston SR, Kschischo M, Swanton C.

Breast Cancer Res Treat. 2014 Nov;148(1):221-9. doi: 10.1007/s10549-014-3153-x. Epub 2014 Oct 7.

PMID:
25288231
39.

Three-dimensional reconstruction of ductal carcinoma in situ with virtual slides.

Booth ME, Treanor D, Roberts N, Magee DR, Speirs V, Hanby AM.

Histopathology. 2015 Jun;66(7):966-73. doi: 10.1111/his.12561. Epub 2015 Feb 5.

40.

Adverse surgical outcomes in screen-detected ductal carcinoma in situ of the breast.

Thomas J, Hanby A, Pinder SE, Ball G, Lawrence G, Maxwell A, Wallis M, Evans A, Dobson H, Clements K, Thompson A; Sloane Project Steering Group.

Eur J Cancer. 2014 Jul;50(11):1880-90. doi: 10.1016/j.ejca.2014.02.023. Epub 2014 May 26.

PMID:
24874088
41.

Pathological evaluation of the staging axillary lymph nodes for breast cancer: a national survey in the United Kingdom.

Verma R, Sundara Rajan S, Verghese ET, Horgan K, Hanby AM, Lane S.

Histopathology. 2014 Nov;65(5):707-11. doi: 10.1111/his.12440. Epub 2014 Aug 5.

PMID:
24750230
42.

Genetic predisposition to in situ and invasive lobular carcinoma of the breast.

Sawyer E, Roylance R, Petridis C, Brook MN, Nowinski S, Papouli E, Fletcher O, Pinder S, Hanby A, Kohut K, Gorman P, Caneppele M, Peto J, Dos Santos Silva I, Johnson N, Swann R, Dwek M, Perkins KA, Gillett C, Houlston R, Ross G, De Ieso P, Southey MC, Hopper JL, Provenzano E, Apicella C, Wesseling J, Cornelissen S, Keeman R, Fasching PA, Jud SM, Ekici AB, Beckmann MW, Kerin MJ, Marme F, Schneeweiss A, Sohn C, Burwinkel B, Guénel P, Truong T, Laurent-Puig P, Kerbrat P, Bojesen SE, Nordestgaard BG, Nielsen SF, Flyger H, Milne RL, Perez JI, Menéndez P, Benitez J, Brenner H, Dieffenbach AK, Arndt V, Stegmaier C, Meindl A, Lichtner P, Schmutzler RK, Lochmann M, Brauch H, Fischer HP, Ko YD; GENICA Network, Nevanlinna H, Muranen TA, Aittomäki K, Blomqvist C, Bogdanova NV, Dörk T, Lindblom A, Margolin S, Mannermaa A, Kataja V, Kosma VM, Hartikainen JM, Chenevix-Trench G; KConFab Investigators, Lambrechts D, Weltens C, Van Limbergen E, Hatse S, Chang-Claude J, Rudolph A, Seibold P, Flesch-Janys D, Radice P, Peterlongo P, Bonanni B, Volorio S, Giles GG, Severi G, Baglietto L, McLean CA, Haiman CA, Henderson BE, Schumacher F, Le Marchand L, Simard J, Goldberg MS, Labrèche F, Dumont M, Kristensen V, Winqvist R, Pylkäs K, Jukkola-Vuorinen A, Kauppila S, Andrulis IL, Knight JA, Glendon G, Mulligan AM, Devillee P, Tollenaar RA, Seynaeve CM, Kriege M, Figueroa J, Chanock SJ, Sherman ME, Hooning MJ, Hollestelle A, van den Ouweland AM, van Deurzen CH, Li J, Czene K, Humphreys K, Cox A, Cross SS, Reed MW, Shah M, Jakubowska A, Lubinski J, Jaworska-Bieniek K, Durda K, Swerdlow A, Ashworth A, Orr N, Schoemaker M, Couch FJ, Hallberg E, González-Neira A, Pita G, Alonso MR, Tessier DC, Vincent D, Bacot F, Bolla MK, Wang Q, Dennis J, Michailidou K, Dunning AM, Hall P, Easton D, Pharoah P, Schmidt MK, Tomlinson I, Garcia-Closas M.

PLoS Genet. 2014 Apr 17;10(4):e1004285. doi: 10.1371/journal.pgen.1004285. eCollection 2014 Apr.

43.

Adding value to rare tissue samples donated to biobanks: characterisation of breast tissue and primary cell cultures obtained from a female-to-male transgender patient.

Millican-Slater R, Good R, Nash C, Heads JA, Pollock S, Chalkley R, Gomm J, Jones JL, Sundara-Rajan S, Horgan K, Hanby AM, Speirs V.

Cell Tissue Bank. 2015 Mar;16(1):27-34. doi: 10.1007/s10561-014-9444-y. Epub 2014 Apr 9.

PMID:
24715474
44.

PSMD9 expression predicts radiotherapy response in breast cancer.

Langlands FE, Dodwell D, Hanby AM, Horgan K, Millican-Slater RA, Speirs V, Verghese ET, Smith L, Hughes TA.

Mol Cancer. 2014 Mar 28;13:73. doi: 10.1186/1476-4598-13-73.

45.

The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer.

Downey CL, Simpkins SA, White J, Holliday DL, Jones JL, Jordan LB, Kulka J, Pollock S, Rajan SS, Thygesen HH, Hanby AM, Speirs V.

Br J Cancer. 2014 Apr 2;110(7):1744-7. doi: 10.1038/bjc.2014.69. Epub 2014 Feb 18.

46.

Systematic review and meta-analysis of cytokeratin 19-based one-step nucleic acid amplification versus histopathology for sentinel lymph node assessment in breast cancer.

Tiernan JP, Verghese ET, Nair A, Pathak S, Kim B, White J, Thygesen H, Horgan K, Hanby AM.

Br J Surg. 2014 Mar;101(4):298-306. doi: 10.1002/bjs.9386. Review.

PMID:
24536007
47.

Assessment of microtubule-associated protein (MAP)-Tau expression as a predictive and prognostic marker in TACT; a trial assessing substitution of sequential docetaxel for FEC as adjuvant chemotherapy for early breast cancer.

Irshad S, Gillett C, Pinder SE, A'hern RP, Dowsett M, Ellis IO, Bartlett JM, Bliss JM, Hanby A, Johnston S, Barrett-Lee P, Ellis P, Tutt A.

Breast Cancer Res Treat. 2014 Apr;144(2):331-41. doi: 10.1007/s10549-014-2855-4. Epub 2014 Feb 12.

PMID:
24519386
48.

Steroid hormone receptor expression in breast cancer stroma.

Booth ME, Hanby AM, Speirs V.

Breast Cancer Res Treat. 2014 Feb;143(3):605-7. doi: 10.1007/s10549-013-2815-4. Epub 2014 Jan 24. No abstract available.

PMID:
24458844
49.

Germline CDH1 mutations in bilateral lobular carcinoma in situ.

Petridis C, Shinomiya I, Kohut K, Gorman P, Caneppele M, Shah V, Troy M, Pinder SE, Hanby A, Tomlinson I, Trembath RC, Roylance R, Simpson MA, Sawyer EJ.

Br J Cancer. 2014 Feb 18;110(4):1053-7. doi: 10.1038/bjc.2013.792. Epub 2013 Dec 24.

50.

The potential utility of geminin as a predictive biomarker in breast cancer.

Sundara Rajan S, Hanby AM, Horgan K, Thygesen HH, Speirs V.

Breast Cancer Res Treat. 2014 Jan;143(1):91-8. doi: 10.1007/s10549-013-2786-5. Epub 2013 Dec 1.

PMID:
24292956

Supplemental Content

Support Center